Bruce Cheson

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Geographic Areas

United States

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Cheson Bruce D
Hematology: The case against rituximab maintenance.
Kelly Jennifer L; Toothaker Stephen R; Ciminello Lauren; Hoelzer Dieter; Holte Harald; LaCasce Ann S; Mead Graham; Thomas Deborah; Van Imhoff Gustaaf W; Kahl Brad S; Cheson Bruce D; Magrath Ian T; Fisher Richard I; Friedberg Jonathan W
Outcomes of patients with burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.
Cheson Bruce D; Cortés Jorge E; Jagannath Sundar
Expanding our mission: Clinical Lymphoma, Myeloma & Leukemia.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Bruce Cheson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Cheson Bruce D
Hematology: The case against rituximab maintenance.
Nature reviews. Clinical oncology 2009;6(11):622-4.
2009: Kelly Jennifer L; Toothaker Stephen R; Ciminello Lauren; Hoelzer Dieter; Holte Harald; LaCasce Ann S; Mead Graham; Thomas Deborah; Van Imhoff Gustaaf W; Kahl Brad S; Cheson Bruce D; Magrath Ian T; Fisher Richard I; Friedberg Jonathan W
Outcomes of patients with burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.
Clinical lymphoma & myeloma 2009;9(4):307-10.
2009: Cheson Bruce D; Cortés Jorge E; Jagannath Sundar
Expanding our mission: Clinical Lymphoma, Myeloma & Leukemia.
Clinical lymphoma & myeloma 2009;9(4):266.
2009: Cheson Bruce D
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
Current opinion in hematology 2009;16(4):299-305.
2009: Cheson Bruce D
The new and ever changing PhRMA guidelines are impeding productive relationship.
Clinical advances in hematology & oncology : H&O 2009;7(6):350.
2009: Cheson Bruce D
Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.
Clinical advances in hematology & oncology : H&O 2009;7(4):263-71.
2009: Cheson Bruce D
Resveratrol and cancer prevention.
Clinical advances in hematology & oncology : H&O 2009;7(3):142.
2009: Cheson Bruce D; Rummel Mathias J
Bendamustine: rebirth of an old drug.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(9):1492-501.
2009: O'Brien Susan M; Claxton David F; Crump Michael; Faderl Stefan; Kipps Thomas; Keating Michael J; Viallet Jean; Cheson Bruce D
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.
Blood 2009;113(2):299-305.
2008: Cheson Bruce D
Adult Burkitt lymphoma: too soon to declare victory.
Oncology (Williston Park, N.Y.) 2008;22(13):1518-9.
2008: Hsi Eric D; Jung Sin-Ho; Lai Raymond; Johnson Jeffrey L; Cook James R; Jones Dan; Devos Sven; Cheson Bruce D; Damon Lloyd E; Said Jonathan
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.
Leukemia & lymphoma 2008;49(11):2081-90.
2008: Cheson Bruce D
Staging and evaluation of the patient with lymphoma.
Hematology/oncology clinics of North America 2008;22(5):825-37, vii-viii.
2008: Cheson Bruce D
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Clinical advances in hematology & oncology : H&O 2008;6(9):4-6.
2008: Cheson Bruce D
Bendamustine: a new therapeutic option for hematologic malignancies.
Clinical advances in hematology & oncology : H&O 2008;6(9):631-3.
2008: Cheson Bruce D; Friedberg Jonathan; Rosen Steven
Recent advances in the treatment of non-hodgkin lymphoma.
Clinical advances in hematology & oncology : H&O 2008;6(9 Suppl 16):1-12.
2008: Robinson K Sue; Williams Michael E; van der Jagt Richard H; Cohen Philip; Herst Jordan A; Tulpule Anil; Schwartzberg Lee S; Lemieux Bernard; Cheson Bruce D
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(27):4473-9.
2008: Cheson Bruce D
Highlights of the 2008 International Conference on Malignant Lymphoma.
Clinical lymphoma & myeloma 2008;8(4):205-8.
2008: Cheson Bruce D; Leonard John P
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.
The New England journal of medicine 2008;359(6):613-26.
2008: Cheson B D
New response criteria for lymphomas in clinical trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 4():iv35-8.
2008: Hallek Michael; Cheson Bruce D; Catovsky Daniel; Caligaris-Cappio Federico; Dighiero Guillaume; Döhner Hartmut; Hillmen Peter; Keating Michael J; Montserrat Emili; Rai Kanti R; Kipps Thomas J;
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.
Blood 2008;111(12):5446-56.
2008: Cheson Bruce D
Recent developments in the treatment of CLL.
Clinical advances in hematology & oncology : H&O 2008;6(5):6-8; quiz 10-2.
2008: Cheson Bruce D; Rai Kanti R; O'Brien Susan
Chronic lymphocytic leukemia: current and emerging treatment approaches.
Clinical advances in hematology & oncology : H&O 2008;6(5 Suppl 13):1-12.
2008: Cheson Bruce D
New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
Radiologic clinics of North America 2008;46(2):213-23, vii.
2008: Cheson Bruce D
Most important accomplishments.
Clinical advances in hematology & oncology : H&O 2008;6(3):150.
2008: Chanan-Khan Asher A; Cheson Bruce D
Lenalidomide for the treatment of B-cell malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1544-52.
2008: Morgan Nancy P; Graves Kristi D; Poggi Elizabeth A; Cheson Bruce D
Implementing an expressive writing study in a cancer clinic.
The oncologist 2008;13(2):196-204.
2008: Smith Sonali M; Grinblatt David; Johnson Jeffrey L; Niedzwiecki Donna; Rizzieri David; Bartlett Nancy L; Cheson Bruce D;
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
British journal of haematology 2008;140(3):313-9.
2008: Fowler Nathan; Asatiani Ekatherine; Cheson Bruce
Needle tract seeding after bone marrow biopsy in non-Hodgkin lymphoma.
Leukemia & lymphoma 2008;49(1):156-8.
2008: Friedberg Jonathan W; Cohen Philip; Chen Ling; Robinson K Sue; Forero-Torres Andres; La Casce Ann S; Fayad Luis E; Bessudo Alberto; Camacho Elber S; Williams Michael E; van der Jagt Richard H; Oliver Jennifer W; Cheson Bruce D
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):204-10.
2008: Gralow Julie; Ozols Robert F; Bajorin Dean F; Cheson Bruce D; Sandler Howard M; Winer Eric P; Bonner James; Demetri George D; Curran Walter; Ganz Patricia A; Kramer Barnett S; Kris Mark G; Markman Maurie; Mayer Robert J; Raghavan Derek; Ramsey Scott; Reaman Gregory H; Sawaya Raymond; Schuchter Lynn M; Sweetenham John W; Vahdat Linda T; Davidson Nancy E; Schilsky Richard L; Lichter Allen S;
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):313-25.
2007: Cheson Bruce D
Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies.
Seminars in oncology 2007;34(6 Suppl 5):S3-7.
2007: Seam Pamela; Juweid Malik E; Cheson Bruce D
The role of FDG-PET scans in patients with lymphoma.
Blood 2007;110(10):3507-16.
2007: Cheson Bruce D
Oblimersen for the treatment of patients with chronic lymphocytic leukemia.
Therapeutics and clinical risk management 2007;3(5):855-70.
2007: Cheson Bruce D
The International Harmonization Project for response criteria in lymphoma clinical trials.
Hematology/oncology clinics of North America 2007;21(5):841-54.
2007: Cheson Bruce D
Although many of the items are natural products, we do not know what harm they might cause in the often excessive quantities that are recommended.
Clinical advances in hematology & oncology : H&O 2007;5(7):499.
2007: Blum Kristie A; Johnson Jeffrey L; Niedzwiecki Donna; Canellos George P; Cheson Bruce D; Bartlett Nancy L
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.
Leukemia & lymphoma 2007;48(7):1313-9.
2007: Cheson Bruce D; Gregory Stephanie A; Marcus Robert
Emerging treatments for indolent lymphoma.
Clinical advances in hematology & oncology : H&O 2007;5(5 Suppl 8):1-9; quiz 11-2.
2007: Cheson Bruce D
Overcoming mechanisms of RECISTance in lymphoma.
Leukemia & lymphoma 2007;48(3):447-8.
2007: Cheson Bruce D
Anti-CD20 Monoclonal Antibodies in the Treatment of Indolent Lymphoma and CLL.
Clinical advances in hematology & oncology : H&O 2007;5(2 Suppl 3):1-16.
2007: Juweid Malik E; Stroobants Sigrid; Hoekstra Otto S; Mottaghy Felix M; Dietlein Markus; Guermazi Ali; Wiseman Gregory A; Kostakoglu Lale; Scheidhauer Klemens; Buck Andreas; Naumann Ralph; Spaepen Karoline; Hicks Rodney J; Weber Wolfgang A; Reske Sven N; Schwaiger Markus; Schwartz Lawrence H; Zijlstra Josee M; Siegel Barry A; Cheson Bruce D;
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(5):571-8.
2007: Cheson Bruce D; Pfistner Beate; Juweid Malik E; Gascoyne Randy D; Specht Lena; Horning Sandra J; Coiffier Bertrand; Fisher Richard I; Hagenbeek Anton; Zucca Emanuele; Rosen Steven T; Stroobants Sigrid; Lister T Andrew; Hoppe Richard T; Dreyling Martin; Tobinai Kensei; Vose Julie M; Connors Joseph M; Federico Massimo; Diehl Volker;
Revised response criteria for malignant lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(5):579-86.
2007: Czuczman Myron S; Porcu Pierluigi; Johnson Jeffrey; Niedzwiecki Donna; Kelly Michael; Hsi Eric D; Cook James R; Canellos George; Cheson Bruce D;
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
Leukemia & lymphoma 2007;48(1):97-103.
2006: Blum Kristie A; Johnson Jeffrey L; Niedzwiecki Donna; Piro Lawrence D; Saven Alan; Peterson Bruce A; Byrd John C; Cheson Bruce D;
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
Cancer 2006;107(12):2817-25.
2006: Cheson Bruce D
The gift that keeps on giving.
Clinical advances in hematology & oncology : H&O 2006;4(11):787.
2006: Cheson Bruce D
Radioimmunotherapy of non-Hodgkin's lymphomas.
Current drug targets 2006;7(10):1293-300.
2006: Smith Sonali M; Johnson Jeffrey L; Niedzwiecki Donna; Eder J Paul; Canellos George; Cheson Bruce D; Bartlett Nancy L; Cancer and Leukemia Group B
Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906.
Leukemia & lymphoma 2006;47(8):1511-7.
2006: Cheson Bruce D
Risky management.
Clinical advances in hematology & oncology : H&O 2006;4(7):481.
2006: Cheson Bruce D; Greenberg Peter L; Bennett John M; Lowenberg Bob; Wijermans Pierre W; Nimer Stephen D; Pinto Antonio; Beran Miloslav; de Witte Theo M; Stone Richard M; Mittelman Moshe; Sanz Guillermo F; Gore Steven D; Schiffer Charles A; Kantarjian Hagop
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
Blood 2006;108(2):419-25.
2006: Cheson Bruce D; Canellos George P
The cancer and leukemia group B lymphoma committee.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 2):3572s-5s.
2006: Cheson Bruce D
CLL response criteria.
Clinical advances in hematology & oncology : H&O 2006;4(5):4-5; discussion 10; suppl 12.
2006: Cheson Bruce D
An oncoethical issue.
Clinical advances in hematology & oncology : H&O 2006;4(4):241.
2006: Cheson Bruce D
Monoclonal antibody therapy for B-cell malignancies.
Seminars in oncology 2006;33(2 Suppl 5):S2-14.
2006: Cheson Bruce D
We need the Annual Oncology Awards.
Clinical advances in hematology & oncology : H&O 2006;4(3):161.
2006: Juweid Malik E; Cheson Bruce D
Positron-emission tomography and assessment of cancer therapy.
The New England journal of medicine 2006;354(5):496-507.
2006: Binet Jacques-Louis; Caligaris-Cappio Federico; Catovsky Daniel; Cheson Bruce; Davis Tom; Dighiero Guillaume; Döhner Hartmut; Hallek Michael; Hillmen Peter; Keating Michael; Montserrat Emili; Kipps Thomas J; Rai Kanti;
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia.
Blood 2006;107(3):859-61.
2006: Cheson Bruce D
Monoclonal antibody therapy of chronic lymphocytic leukemia.
Cancer immunology, immunotherapy : CII 2006;55(2):188-96.
2005: Kelloff Gary J; Krohn Kenneth A; Larson Steven M; Weissleder Ralph; Mankoff David A; Hoffman John M; Link Jeanne M; Guyton Kathryn Z; Eckelman William C; Scher Howard I; O'Shaughnessy Joyce; Cheson Bruce D; Sigman Caroline C; Tatum James L; Mills George Q; Sullivan Daniel C; Woodcock Janet
The progress and promise of molecular imaging probes in oncologic drug development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(22):7967-85.
2005: Cheson Bruce D
CT/PET scan.
Clinical advances in hematology & oncology : H&O 2005;3(9):483.
2005: Cheson Bruce D
Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(26):6283-4.
2005: Juweid Malik E; Cheson Bruce D
Role of positron emission tomography in lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(21):4577-80.
2005: Juweid Malik E; Wiseman Gregory A; Vose Julie M; Ritchie Justine M; Menda Yusuf; Wooldridge James E; Mottaghy Felix M; Rohren Eric M; Blumstein Norbert M; Stolpen Alan; Link Brian K; Reske Sven N; Graham Michael M; Cheson Bruce D
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(21):4652-61.
2005: Cheson Bruce D; Haller Daniel; Horning Sandra J
Serving interests in hematologic malignancies in the journal of clinical oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3666-7.
2005: Kelloff Gary J; Hoffman John M; Johnson Bruce; Scher Howard I; Siegel Barry A; Cheng Edward Y; Cheson Bruce D; O'shaughnessy Joyce; Guyton Kathryn Z; Mankoff David A; Shankar Lalitha; Larson Steven M; Sigman Caroline C; Schilsky Richard L; Sullivan Daniel C
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(8):2785-808.
2005: Cheson Bruce D; Dutcher Bonni S
Managing malignancy-associated hyperuricemia with rasburicase.
The journal of supportive oncology 2005;3(2):117-24.
2005: Cheson Bruce D
Letter from the editor.
Clinical advances in hematology & oncology : H&O 2005;3(1):5.
2005: Cheson Bruce D
The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2005;19(5):309-22.
2004: Ozdemirli Metin; Cheson Bruce; Jaffe Elaine S
What is anaplastic large cell lymphoma?
The American journal of surgical pathology 2004;28(12):1664-5; author reply 1665-7.
2004: Cheson Bruce D
Letter from the editor.
Clinical advances in hematology & oncology : H&O 2004;2(11):695.
2004: Cheson Bruce D
The Peoria Principle.
Clinical advances in hematology & oncology : H&O 2004;2(10):627.
2004: Asatiani Ekatherine; Cohen Philip; Ozdemirli Metin; Kessler Craig M; Mavromatis Blanche; Cheson Bruce D
Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement.
American journal of hematology 2004;77(2):144-6.
2004: Cheson Bruce D
What is new in lymphoma?
CA: a cancer journal for clinicians 2004;54(5):260-72.
2004: Mavromatis Blanche H; Cheson Bruce D
Novel therapies for chronic lymphocytic leukemia.
Blood reviews 2004;18(2):137-48.
2004: Cheson Bruce D
Overview of the revised response criteria for acute myelogenous leukemia.
Clinical advances in hematology & oncology : H&O 2004;2(5):277-9.
2004: Cheson Bruce D
Letter from the editor.
Clinical advances in hematology & oncology : H&O 2004;2(3):139.
2003: Cheson Bruce D; Bennett John M; Kopecky Kenneth J; Büchner Thomas; Willman Cheryl L; Estey Elihu H; Schiffer Charles A; Doehner Hartmut; Tallman Martin S; Lister T Andrew; Lo-Coco Francesco; Willemze Roel; Biondi Andrea; Hiddemann Wolfgang; Larson Richard A; Löwenberg Bob; Sanz Miguel A; Head David R; Ohno Ryuzo; Bloomfield Clara D;
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4642-9.
2003: Kauh John; Baidas Said M; Ozdemirli Metin; Cheson Bruce D
Mantle cell lymphoma: clinicopathologic features and treatments.
Oncology (Williston Park, N.Y.) 2003;17(6):879-91, 896; discussion 896-8.
2003: Mavromatis Blanche; Cheson Bruce D
Monoclonal antibody therapy of chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1874-81.
2003: Cheson Bruce D
Radioimmunotherapy of non-Hodgkin lymphomas.
Blood 2003;101(2):391-8.
2003: Cheson Bruce D
Oral fludarabine: a viewpoint by Bruce D. Cheson.
Drugs 2003;63(21):2325.
2002: Mavromatis Blanche H; Cheson Bruce D
Pre- and post-treatment evaluation of non-Hodgkin's lymphoma.
Best practice & research. Clinical haematology 2002;15(3):429-47.
2002: Hegde Upendra P; Wilson Wyndham H; White Therese; Cheson Bruce D
Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia.
Blood 2002;100(6):2260-2.
2002: Cheson Bruce D
Hematologic malignancies: new developments and future treatments.
Seminars in oncology 2002;29(4 Suppl 13):33-45.
2002: Diehl Volker; Cheson Bruce D
Bendamustine in the treatment of hematologic malignancies. Introduction.
Seminars in oncology 2002;29(4 Suppl 13):1-3.
2002: Wright John J; Zerivitz Kenn; Gravell Amy E; Cheson Bruce D
Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra).
Oncology (Williston Park, N.Y.) 2002;16(7):930-1, 935-7.
2002: Cheson Bruce D; West Pamela J
Clinical trials referral resource. Current clinical trials in non-Hodgkin's lymphoma.
Oncology (Williston Park, N.Y.) 2002;16(6):762-3, 766.
2002: Conley Barbara A; Enos Rebecca A; Cheson Bruce D
Clinical trials referral resource. Targeted therapy in squamous cell cancers of the head and neck.
Oncology (Williston Park, N.Y.) 2002;16(5):621-2, 625-6.
2002: Wilson Wyndham H; Grossbard Michael L; Pittaluga Stefania; Cole Diane; Pearson Deborah; Drbohlav Nicole; Steinberg Seth M; Little Richard F; Janik John; Gutierrez Martin; Raffeld Mark; Staudt Louis; Cheson Bruce D; Longo Dan L; Harris Nancy; Jaffe Elaine S; Chabner Bruce A; Wittes Robert; Balis Frank
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Blood 2002;99(8):2685-93.
2002: Smith Malcolm A; Murgo Anthony J; Wright John J; Schoenfeldt Mason; Cheson Bruce D
Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancer.
Oncology (Williston Park, N.Y.) 2002;16(3):328, 331-3, 338 passim.
2002: Gertz Morie A; Lacy Martha Q; Dispenzieri Angela; Cheson Bruce D; Barlogie Bart; Kyle Robert A; Palladini Giovanni; Geyer Susan M; Merlini Giampaolo
A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL).
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2002;9(1):24-30.
2002: Cheson Bruce
Bexxar (Corixa/GlaxoSmithKline).
Current opinion in investigational drugs (London, England : 2000) 2002;3(1):165-70.
2002: Anderson Barry D; Mason Schoenfeldt; Cheson Bruce D
Clinical trials referral resource. Current clinical trials in neuroblastoma.
Oncology (Williston Park, N.Y.) 2002;16(1):82-4, 86, 89.
2002: Cheson Bruce D
CHOP plus rituximab--balancing facts and opinion.
The New England journal of medicine 2002;346(4):280-2.
2002: Cheson Bruce D
Rituximab: clinical development and future directions.
Expert opinion on biological therapy 2002;2(1):97-110.
2002: Vose Julie M; Chiu Brian C-H; Cheson Bruce D; Dancey Janet; Wright John
Update on epidemiology and therapeutics for non-Hodgkin's lymphoma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;():241-62.
2001: Cheson B D; Bennett J M; Kantarjian H; Schiffer C A; Nimer S D; Löwenberg B; Stone R M; Mittelman M; Sanz G F; Wijermans P W; Greenberg P L
Myelodysplastic syndromes standardized response criteria: further definition.
Blood 2001;98(6):1985.
2001: Chen H X; Gore-Langton R E; Cheson B D
Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab.
Oncology (Williston Park, N.Y.) 2001;15(8):1017, 1020, 1023-6.
2001: Murgo A; Wood K F; Gravell A E; Cheson B D
Clinical trials referral resource. ST1571.
Oncology (Williston Park, N.Y.) 2001;15(7):881-2, 885-6.
2001: Cheson B D
New drug development in non-Hodgkin lymphomas.
Current oncology reports 2001;3(3):250-9.
2000: Cheson B D; Bennett J M; Kantarjian H; Pinto A; Schiffer C A; Nimer S D; Löwenberg B; Beran M; de Witte T M; Stone R M; Mittelman M; Sanz G F; Wijermans P W; Gore S; Greenberg P L;
Report of an international working group to standardize response criteria for myelodysplastic syndromes.
Blood 2000;96(12):3671-4.
2000: Gutierrez M; Chabner B A; Pearson D; Steinberg S M; Jaffe E S; Cheson B D; Fojo A; Wilson W H
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(21):3633-42.
2000: Cheson B D; Zwiebel J A; Dancey J; Murgo A
Novel therapeutic agents for the treatment of myelodysplastic syndromes.
Seminars in oncology 2000;27(5):560-77.
2000: Cheson B D
Emerging therapies and future directions in chronic lymphocytic leukaemia--chemotherapy.
Hematology and cell therapy 2000;42(1):41-7.
2000: Grillo-López A J; Cheson B D; Horning S J; Peterson B A; Carter W D; Varns C L; Klippenstein D L; Shen C D
Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(4):399-408.
2000: Kalil N; Cheson B D
Management of chronic lymphocytic leukaemia.
Drugs & aging 2000;16(1):9-27.
1999: Cheson B D
New chemotherapeutics strategies for the treatment of indolent lymphoid malignancies.
Seminars in hematology 1999;36(4 Suppl 5):26-33.
1999: Cheson B D
Future strategies toward the cure of indolent B-cell malignancies: introduction.
Seminars in hematology 1999;36(4 Suppl 5):1-2.
1999: Cheson B D; Vena D A; Barrett J; Freidlin B
Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2454-60.
1999: Ivy S P; Blatner G; Cheson B D
Clinical trials referral resource. Clinical trials of combination regimens containing oxaliplatin.
Oncology (Williston Park, N.Y.) 1999;13(8):1116-8.
1999: Ivy S P; Blatner G; Cheson B D
Clinical trials referral resource. Clinical trials of single-agent oxaliplatin.
Oncology (Williston Park, N.Y.) 1999;13(7):966, 969-70.
1999: Ivy S P; Blatner G; Cheson B D
Clinical trials referral resource. Clinical trials with gadolinium-texaphyrin and lutetium-texaphyrin.
Oncology (Williston Park, N.Y.) 1999;13(5):671, 674-6.
1999: Cheson B D; Horning S J; Coiffier B; Shipp M A; Fisher R I; Connors J M; Lister T A; Vose J; Grillo-López A; Hagenbeek A; Cabanillas F; Klippensten D; Hiddemann W; Castellino R; Harris N L; Armitage J O; Carter W; Hoppe R; Canellos G P
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1244.
1999: Kalil N; Cheson B D
Chronic lymphocytic leukemia.
The oncologist 1999;4(5):352-69.
1998: Cheson B D
Current approaches to therapy for indolent non-Hodgkin's lymphoma.
Oncology (Williston Park, N.Y.) 1998;12(10 Suppl 8):25-34.
1998: Cheson B D; Sorensen J M; Vena D A; Montello M J; Barrett J A; Damasio E; Tallman M; Annino L; Connors J; Coiffier B; Lauria F
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):3007-15.
1998: Cheson B D
Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation.
Seminars in hematology 1998;35(3 Suppl 3):14-21.
1998: Cheson B D
New prospects in the treatment of indolent lymphomas with purine analogues.
The cancer journal from Scientific American 1998;4 Suppl 2():S27-36.
1998: Wilson W H; Little R; Pearson D; Jaffe E S; Steinberg S M; Cheson B D; Humphrey R; Kohler D R; Elwood P
Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2345-51.
1998: Cheson B D; Frame J N; Vena D; Quashu N; Sorensen J M
Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2313-20.
1998: Cheson B D
Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes.
Leukemia research 1998;22 Suppl 1():S17-21.
1998: Zwiebel J A; Cheson B D
Chronic lymphocytic leukemia: staging and prognostic factors.
Seminars in oncology 1998;25(1):42-59.
1997: Murgo A J; Cannon D; Christian M C; Cheson B; Nelson A P
Clinical trials referral resource. Clinical trials with pyrazoloacridine.
Oncology (Williston Park, N.Y.) 1997;11(7):991-4.
1997: Cheson B D; Nelson A A
Clinical trials referral resource. Clinical trials with PSC-833.
Oncology (Williston Park, N.Y.) 1997;11(4):490, 493.
1997: Feigal E G; Phillips P H; Cheson B D
Clinical Trials Referral Resource. Clinical trials in AIDS related malignancies.
Oncology (Williston Park, N.Y.) 1997;11(3):337-8, 341.
1997: Cheson B D; Phillips P H
Clinical trials referral resource. New autologous stem-cell transplant protocols.
Oncology (Williston Park, N.Y.) 1997;11(2):178-80.
1997: Sorensen J M; Vena D A; Fallavollita A; Chun H G; Cheson B D
Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):458-65.
1997: Arbuck S G; Sorensen J M; Christian M C; Ho P; Pluda J M; Cheson B D
New drugs in non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8 Suppl 1():119-28.
1996: Cheson B D
Perspectives on purine analogues.
Hematology and cell therapy 1996;38 Suppl 2():S109-16.
1996: Sorensen J M; Cheson B D; Phillips P H
Clinical trials referral resource. Clinical trials with tomudex.
Oncology (Williston Park, N.Y.) 1996;10(7):1041-2.
1996: Sorensen J M; Phillips P H; Cheson B D
Clinical trials referral resource. Clinical trials using gemcitabine.
Oncology (Williston Park, N.Y.) 1996;10(6):855-6.
1996: Cheson B D; Bennett J M; Grever M; Kay N; Keating M J; O'Brien S; Rai K R
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
Blood 1996;87(12):4990-7.
1996: Brawley O W; Cheson B D; Phillips P H
Clinical trials referral resource. Cancer chemoprevention and control trials.
Oncology (Williston Park, N.Y.) 1996;10(4):499-500.
1996: Brawley O W; Phillips P H; Cheson B D
Cancer chemoprevention trials.
Oncology (Williston Park, N.Y.) 1996;10(3):324-7.
1996: Brawley O W; Cheson B D; Phillips P H
Clinical trials referral resource. Breast cancer and prostate cancer.
Oncology (Williston Park, N.Y.) 1996;10(1):100, 102.
1995: Cheson B D; Abrams J; McCabe M S; Crosson K
Clinical trials referral resource.
Oncology (Williston Park, N.Y.) 1995;9(12):1292, 1297-8.
1995: Cheson B D; McCabe M S; Phillips P H
Clinical trials. Referral resource. Clinical trials assessing quality of life.
Oncology (Williston Park, N.Y.) 1995;9(11):1171-4, 1176, 1178.
1995: Cheson B D
Infectious and immunosuppressive complications of purine analog therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2431-48.
1995: Cheson B D; Foss F M; Phillips P H
Clinical Trials Referral Resource: Mycosis Fungoides/Sézary Syndrome.
Oncology (Williston Park, N.Y.) 1995;9(7):645-6.
1995: Cheson B D; Wilson W H; Phillips P H
Clinical trials at the medicine branch of the NCI-part 2.
Oncology (Williston Park, N.Y.) 1995;9(6):506, 509-10.
1995: Wilson W H; Chabner B A; Bryant G; Bates S; Fojo A; Regis J; Jaffe E S; Steinberg S M; Goldspiel B R; Cheson B D
Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(2):381-6.
1994: Cheson B D; Vena D A; Foss F M; Sorensen J M
Neurotoxicity of purine analogs: a review.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(10):2216-28.
1994: Cheson B D; Kaplan R S; Phillips P H
Clinical trials referral resource. Primary central nervous system tumors.
Oncology (Williston Park, N.Y.) 1994;8(10):51-2, 55.
1994: Cheson B D
Chronic lymphocytic leukemia and hairy-cell leukemia.
Current opinion in hematology 1994;1(4):268-77.
1994: Cheson B D; Phillips P H; Trimble E
Clinical trials. Referral resource. Phase II Ovarian Cancer Trials.
Oncology (Williston Park, N.Y.) 1994;8(4):73-4.
1994: Cheson B D; Trimble E; Phillips P H
Clinical trials referral resource. Ovarian cancer: phase II trials.
Oncology (Williston Park, N.Y.) 1994;8(3):56, 59, 63.
1994: Cheson B D; Phillips P H; Feigal E G
Clinical trials referral resource. Non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 1994;8(2):56, 61, 65.
1993: Cheson B D; Feigal E G; Phillips P H
Clinical trials referral resource. Extensive-stage small-cell lung cancer.
Oncology (Williston Park, N.Y.) 1993;7(11):60, 63-4.
1993: Cheson B D; Feigal E G; Phillips P H
Clinical trials referral resource. Small-cell lung cancer.
Oncology (Williston Park, N.Y.) 1993;7(10):43-7.
1993: Parkinson D R; Sznol M; Cheson B D
Biologic therapies for low-grade lymphomas.
Seminars in oncology 1993;20(5 Suppl 5):111-7.
1993: Cheson B D
New chemotherapeutic agents for the treatment of low-grade non-Hodgkin's lymphomas.
Seminars in oncology 1993;20(5 Suppl 5):96-110.
1993: Wilson W H; Bryant G; Bates S; Fojo A; Wittes R E; Steinberg S M; Kohler D R; Jaffe E S; Herdt J; Cheson B D
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1573-82.
1993: Feigal E G; Christian M; Cheson B; Grever M; Friedman M A
New chemotherapeutic agents in non-small-cell lung cancer.
Seminars in oncology 1993;20(2):185-201.
1993: Cheson B D
Purine analogs in lymphoproliferative disorders.
Leukemia & lymphoma 1993;11 Suppl 2():153-9.
1992: Parkinson D R; Smith M A; Cheson B D; Stevenson H C; Friedman M A
Trans-retinoic acid and related differentiation agents.
Seminars in oncology 1992;19(6):734-41.
1992: Cheson B D
New antimetabolites in the treatment of human malignancies.
Seminars in oncology 1992;19(6):695-706.
1992: Gotay C C; Korn E L; McCabe M S; Moore T D; Cheson B D
Building quality of life assessment into cancer treatment studies.
Oncology (Williston Park, N.Y.) 1992;6(6):25-8; discussion 30-2, 37.
1992: Smith M A; Parkinson D R; Cheson B D; Friedman M A
Retinoids in cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):839-64.
1992: Gotay C C; Korn E L; McCabe M S; Moore T D; Cheson B D
Quality-of-life assessment in cancer treatment protocols: research issues in protocol development.
Journal of the National Cancer Institute 1992;84(8):575-9.
1992: Cheson B D
Chemotherapy and bone marrow transplantation for myelodysplastic syndromes.
Seminars in oncology 1992;19(1):85-94.
1991: Cheson B D
Clinical trials referral resource. Protocols for elderly patients with acute myeloid leukemia.
Oncology (Williston Park, N.Y.) 1991;5(11):61-2, 65.
1991: Cheson B D
Cancer clinical trials. Clinical trials programs.
Seminars in oncology nursing 1991;7(4):235-42.
1991: Cheson B D
New chemotherapeutic agents for non-Hodgkin's lymphomas.
Hematology/oncology clinics of North America 1991;5(5):1027-51.
1991: Cheson B D
New modalities of therapy in chronic lymphocytic leukemia.
Critical reviews in oncology/hematology 1991;11(3):167-77.
1991: Moore T D; Phillips P H; Nerenstone S R; Cheson B D
Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(6):1071-88.
1991: Cheson B D
Clinical trials referral resource. Adjuvant therapy for rectal cancer.
Oncology (Williston Park, N.Y.) 1991;5(5):61-2, 64.
1991: Cheson B D
Clinical trials referral resource.
Oncology (Williston Park, N.Y.) 1991;5(2):116, 118.
1991: Cheson B D
Chronic lymphocytic leukemia and hairy-cell leukemia.
Current opinion in oncology 1991;3(1):54-62.
1991: Chun H G; Leyland-Jones B; Cheson B D
Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(1):175-88.
1990: Cheson B D
Issues for the future development of fludarabine phosphate.
Seminars in oncology 1990;17(5 Suppl 8):71-8.
1990: Cheson B D
Fludarabine phosphate--looking forward.
Seminars in oncology 1990;17(5 Suppl 8):1-2.
1990: Cheson B D
Recent advances in the treatment of B-cell chronic lymphocytic leukemia.
Oncology (Williston Park, N.Y.) 1990;4(9):71-8, 83-4; disc. 84, 87-8, 90 pass.
1990: Cheson B D
The myelodysplastic syndromes: current approaches to therapy.
Annals of internal medicine 1990;112(12):932-41.
1990: Grem J L; Rubinstein L; King S A; Cheson B D; Hawkins M J; Shoemaker D D
Clinical toxicity associated with tiazofurin.
Investigational new drugs 1990;8(2):227-38.
1990: Cheson B D; Cassileth P A; Head D R; Schiffer C A; Bennett J M; Bloomfield C D; Brunning R; Gale R P; Grever M R; Keating M J
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(5):813-9.
1990: Simon R; Durrleman S; Hoppe R T; Bonadonna G; Bloomfield C D; Rudders R A; Cheson B D; Berard C W
Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: experience of the non-Hodgkin's Lymphoma Pathologic Classification Project.
Medical and pediatric oncology 1990;18(2):89-96.
1989: Durrleman S; Grem J L; Cheson B D
2'-Deoxycoformycin after failure of alpha-interferon in hairy cell leukemia.
European journal of haematology 1989;43(4):297-302.
1989: Cheson B D
Current approaches to the chemotherapy of B-cell chronic lymphocytic leukemia: a review.
American journal of hematology 1989;32(1):72-7.
1989: Cheson B D; Bennett J M; Rai K R; Grever M R; Kay N E; Oken M M; Schiffer C A; Keating M J; Boldt D H; Kempin S J
Chronic lymphocytic leukemia: recommendations.
Annals of internal medicine 1989;110(8):664-5.
1989: Grem J L; King S A; Cheson B D; Leyland-Jones B; Wittes R E
Pentostatin in hairy cell leukemia: treatment by the special exception mechanism.
Journal of the National Cancer Institute 1989;81(6):448-53.
1989: Cheson B D; Lacerna L; Leyland-Jones B; Sarosy G; Wittes R E
Autologous bone marrow transplantation. Current status and future directions.
Annals of internal medicine 1989;110(1):51-65.
1988: Simon R; Durrleman S; Hoppe R T; Bonadonna G; Bloomfield C D; Rudders R A; Cheson B D; Berard C W
The Non-Hodgkin Lymphoma Pathologic Classification Project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas.
Annals of internal medicine 1988;109(12):939-45.
1988: Cheson B D; Bennett J M; Rai K R; Grever M R; Kay N E; Schiffer C A; Oken M M; Keating M J; Boldt D H; Kempin S J
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group.
American journal of hematology 1988;29(3):152-63.
1988: Sarosy G; Leyland-Jones B; Soochan P; Cheson B D
The systemic administration of intravenous melphalan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(11):1768-82.
1988: Grem J L; Cheson B D; King S A; Leyland-Jones B; Suffness M
Cephalotaxine esters: antileukemic advance or therapeutic failure?
Journal of the National Cancer Institute 1988;80(14):1095-103.
1988: O'Dwyer P J; Cheson B D; Leyland-Jones B; King S A; Hoth D F
Deoxycoformycin: an active new drug for indolent lymphomas and hairy cell leukemia.
Oncology (Williston Park, N.Y.) 1988;2(6):17-23, 26-7.
1988: O'Dwyer P J; Wagner B; Leyland-Jones B; Wittes R E; Cheson B D; Hoth D F
2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.
Annals of internal medicine 1988;108(5):733-43.
1988: Cheson B D
Study design in chronic lymphocytic leukemia.
Nouvelle revue française d'hématologie 1988;30(5-6):407-10.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Bruce Cheson

Research Profile (preview)

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Geographic Areas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Bruce Cheson (preview)

All Publications